Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Smaglo on the Future of Immunotherapy in Gastric Cancer

June 15th 2020

Brandon G. Smaglo, MD, FACP, discusses the future of immunotherapy in gastric cancer.

FDA Grants DKN-01 Orphan Drug Status for Gastric/GEJ Cancer

June 12th 2020

The FDA has granted an Orphan Drug designation to DKN-01 for the treatment of patients with gastric cancer or gastroesophageal junction cancer.

Dr. Mizrahi on Addition of PARP Inhibitors to Chemotherapy in Mutated Pancreatic Cancer

June 11th 2020

Jonathan Mizrahi, MD, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.

FDA Approves Nivolumab for Esophageal Cancer

June 11th 2020

The FDA has approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Dr. Musher on Immunotherapy Versus TKIs in HCC

June 10th 2020

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.

Philip Highlights Promise of Devimistat in Pancreatic Cancer

June 9th 2020

Philip A. Philip, MD, PhD, FRCP, discusses challenges in pancreatic cancer and the emergence of devimistat in the treatment paradigm.

Dr. Musher on Immunotherapy Versus TKIs in HCC

June 9th 2020

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.

Philip Highlights Promise of Devimistat in Pancreatic Cancer

June 9th 2020

Philip A. Philip, MD, PhD, FRCP, discusses challenges in pancreatic cancer and the emergence of devimistat in the treatment paradigm.

Shah Highlights Novel Agents in Gastrointestinal Cancers

June 8th 2020

Manish A. Shah, MD, discusses the emerging agent zolbetuximab and the antibody-drug conjugate trastuzumab deruxtecan as treatment options for patients with gastric and GEJ cancers.

Shah Highlights Novel Agents in Gastric Cancer

June 8th 2020

Manish A. Shah, MD, discusses the emerging agent zolbetuximab and the antibody-drug conjugate trastuzumab deruxtecan as treatment options for patients with gastric and GEJ cancers.

Exploring New Treatment Options In HCC

June 8th 2020

This Onclive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC. Join us Thursday, June 23, 2020 at 8 PM EST.

FDA Grants Margetuximab Orphan Drug Status for Gastric Cancer

June 5th 2020

The FDA has granted margetuximab an Orphan Drug designation for the treatment of patients with gastric and gastroesophageal junction cancer.

Dr. Nelson on the Future Utility of ctDNA in CRC

June 5th 2020

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Dr. Simeone on the Importance of Germline Testing in Pancreatic Cancer

June 5th 2020

Diane M. Simeone, MD, discusses the importance of germline testing in pancreatic cancer.

Dr. Armaghany on the Utility of ctDNA in CRC

June 4th 2020

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Dr. Lenz on the Updated Findings From the CheckMate-142 Trial in mCRC

June 4th 2020

Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Encorafenib Plus Cetuximab Approved in Europe for BRAF V600E-Mutant mCRC

June 3rd 2020

The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.

Continued OS Advantage With Encorafenib/Cetuximab Cements Role in BRAF+ mCRC

June 3rd 2020

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC

June 3rd 2020

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.